Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Decision Diagnostics Corp. (OTC: DECN).

Full DD Report for DECN

You must become a subscriber to view this report.


Recent News from (OTC: DECN)

Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ)
LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and...
Source: ACCESSWIRE
Date: April, 18 2018 09:15
Decision Diagnostics Discusses Culmination of Patent Case Against J&J and Its Divisions Based on The Federal Doctrine of Equivalents
DECN Believes that Health Industry Giant is Employing Very Risky Summary Judgment Strategy in $400 Million Case LOS ANGELES, CA / ACCESSWIRE / March 27, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN ), is the manufacturer, quality plan administrator and the exclusive worldwide sal...
Source: ACCESSWIRE
Date: March, 27 2018 09:15
Decision Diagnostics' Panacea Genprecis! Product Moves into Pre-Production, First Round Clinical Trials to Begin in the Next 30 Days
Initial Testing Proves DECN's GenPrecis! System is Performing Above and Beyond Published Standards, Looking Toward Becoming an Industry Legacy in its Own Right LOS ANGELES, CA / ACCESSWIRE / March 21, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan ad...
Source: ACCESSWIRE
Date: March, 21 2018 09:15
Decision Diagnostics' Fundamental Genchoice! Diabetic Test Strip Moves into Formal Managed Clinical Trials and Advanced Testing for Upcoming 510k Filing with U.S. FDA
DECN Anticipates Initial International Sales of 165,000 Genchoice! B oxes Per Month as it also Readies Panacea Genprecis! System, and as Hybrid Private Label Plan Reaches Intensity LOS ANGELES, CA / ACCESSWIRE / March 13, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manuf...
Source: ACCESSWIRE
Date: March, 13 2018 09:15
Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model
LOS ANGELES, CA / ACCESSWIRE / January 3, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ ("S...
Source: ACCESSWIRE
Date: January, 03 2018 09:15
Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model
Decision Diagnostics Announces 2018 Business Focus Through the Introduction of New Products, Positive Conclusion to J&J Litigation, and Hybrid Private Label Business Model
Source: OTC Markets
Date: January, 03 2018 00:00
Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip
GenAccord!™ Offers Newly Innovative "Either / Or" Technology, Allowing the Test Strip to Work on More Than One Legacy Diabetic Meter LOS ANGELES, CA / ACCESSWIRE / December 20, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA ...
Source: ACCESSWIRE
Date: December, 20 2017 09:20
Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip
Decision Diagnostics Provides Additional Commentary About Its New GenAccord!(TM) Diabetic Test Strip
Source: OTC Markets
Date: December, 20 2017 00:00
Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology
LOS ANGELES, CA / ACCESSWIRE / December 14, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is a manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate!™ (...
Source: ACCESSWIRE
Date: December, 14 2017 09:15
Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology
Decision Diagnostics Announces New GenAccord!(TM), Diabetic Test Strip with First Use of Its GenPrecis!(TM) Full Spread Electrode Technology
Source: OTC Markets
Date: December, 14 2017 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-07-200.0450.04220.0460.0422151,872
2018-07-190.042940.050.0510.04294365,068
2018-07-18N/A0.0464N/AN/A2
2018-07-170.0460.04640.04650.042142,686
2018-07-160.0550.050.0550.0465211,384

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-07-2036,900151,87224.2968Cover
2018-07-19234,588365,06864.2587Short
2018-07-1780,300142,68656.2774Short
2018-07-16161,384211,38476.3464Short
2018-07-13285,047362,81478.5656Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DECN.


About Decision Diagnostics Corp. (OTC: DECN)

Logo for Decision Diagnostics Corp. (OTC: DECN)

Decision Diagnostics Corp. is a nationwide prescription and non prescription diagnostics and home testing products distributor. We also market our Genstrip , GenUltimate and GenSure Glucose Test Strip for diabetics, the first alternative glucose testing strips sold to the market in this decade and the first alternative test strip products sold into the market since early .

 

 

 

Current Management

  • Keith M Berman / CFO
    • Chief Financial Officer, Secretary and Director Specializing in invitro diagnostics and healthcare software including intranet and Internet systems for the past years and a founder of Decision Diagnostics Corp., Keith Berman brings more than years experience in the healthcare field, having worked with such companies as Technicon Corporation and BoehringerMannheim Corporation. He is the founder of Medicius Inc., and served as that company s president at the time of its acquisition by what is today, Decision Diagnostics Corp. Mr. Berman also was the founder of Cymedix, the operating division of the formerly Amex traded Ramp Corp. formerly Medix Resources AMEX: RCO , a public company. Mr. Berman received his B.A. and M.B.A. from Indiana University.
  • Robert Jagunich / Chairman
    • Chairman and Director Robert Jagunich brings years of experience in the medical systems and device industry. Since joining Decision Diagnostics Corp., Mr. Jagunich has also served president at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. From April through December , he served as a director of Cymedix Corporation, the operating division of Ramp Corp. AMEX: RCO . Mr. Jagunich also has provided consulting services to such clients as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. He received his B.S., M.S. and M.B.A. from the University of Michigan.

Current Share Structure

  • Market Cap: $4,544,061 - 03/09/2018
  • Authorized: 494,995,000 - 05/08/2017
  • Issue and Outstanding: 90,881,210 - 05/08/2017
  • Float: 79,519,393 - 05/08/2017

 


Recent Filings from (OTC: DECN)

Quarterly Report - OTC PINK 3Q 2017 BALANCE SHEET_FOOTNOTES_STATEMENTS OF CASH FLOWS & EQUITY REVISED
Filing Type: Quarterly Report - OTC PINK 3Q 2017 BALANCE SHEET_FOOTNOTES_STATEMENTS OF CASH FLOWS & EQUITY REFiling Source: OTC Markets
Filing Date: November, 17 2017
Supplemental Information - OTC PINK QUARTERLY REPORT 3Q 2017
Filing Type: Supplemental Information - OTC PINK QUARTERLY REPORT 3Q 2017Filing Source: OTC Markets
Filing Date: November, 14 2017
Management Discussion and Analysis - OTC PINK QUARTERLY REPORT FOR 3Q 2017
Filing Type: Management Discussion and Analysis - OTC PINK QUARTERLY REPORT FOR 3Q 2017Filing Source: OTC Markets
Filing Date: November, 14 2017
Supplemental Information - OTC PINK QUARTERLY REPORT FOR 2Q 2017 SUPPLEMENTAL INFORMATION
Filing Type: Supplemental Information - OTC PINK QUARTERLY REPORT FOR 2Q 2017 SUPPLEMENTAL INFORMATIONFiling Source: OTC Markets
Filing Date: August, 15 2017
Management Discussion and Analysis - OTC PINK QUARTERLY REPORT 2Q 2017 MANAGEMENTS' DISCUSSION & ANALYSIS (amended)
Filing Type: Management Discussion and Analysis - OTC PINK QUARTERLY REPORT 2Q 2017 MANAGEMENTS' DISCUSSION &Filing Source: OTC Markets
Filing Date: August, 15 2017
Quarterly Report - OTC PINK QUARTERLY REPORT FOR 2Q 2017 BALANCE SHEET_FOOTNOTES & STATEMENTS OF CASH FLOWS & EQUITY
Filing Type: Quarterly Report - OTC PINK QUARTERLY REPORT FOR 2Q 2017 BALANCE SHEET_FOOTNOTES & STATEMENTS OFiling Source: OTC Markets
Filing Date: August, 14 2017
Officer/Director Disclosure - William Lyons Resigns DECN Board of Directors
Filing Type: Officer/Director Disclosure - William Lyons Resigns DECN Board of DirectorsFiling Source: OTC Markets
Filing Date: July, 20 2017
Officer/Director Disclosure - ROBERT JAGUNICH RE=ELECTED TO DECN BOARD OF DIRECTORS AFTER SHORT RETIREMENT
Filing Type: Officer/Director Disclosure - ROBERT JAGUNICH RE=ELECTED TO DECN BOARD OF DIRECTORS AFTER SHORT RETIFiling Source: OTC Markets
Filing Date: June, 22 2017
Officer/Director Disclosure - DECN CHAIRMAN ROBERT JAGUNICH RETIRES FROM BOARD OF DIRECTORS
Filing Type: Officer/Director Disclosure - DECN CHAIRMAN ROBERT JAGUNICH RETIRES FROM BOARD OF DIRECTORSFiling Source: OTC Markets
Filing Date: May, 31 2017
Quarterly Report - OTC PINK QUARTERLY REPORT 1Q2017 BALANCE SHEET_FOOTNOTES & STATEMENTS OF EQUITY AND CASH FLOWS
Filing Type: Quarterly Report - OTC PINK QUARTERLY REPORT 1Q2017 BALANCE SHEET_FOOTNOTES & STATEMENTS OF EQUIFiling Source: OTC Markets
Filing Date: May, 26 2017

 

 


Daily Technical Chart for (OTC: DECN)

Daily Technical Chart for (OTC: DECN)


Stay tuned for daily updates and more on (OTC: DECN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DECN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DECN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of DECN and does not buy, sell, or trade any shares of DECN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/